Ullman Medical ^{For Profit}

Ullman Medical has identified and developed a novel botanical extract which demonstrated positive human clinical data in treating psoriasis and pre-clinical evidence of non-toxic, anti-angiogenesis properties important in the treatment of eye diseases, arthritis, and certain cancers. The company’s objective is the commercialization of this plant-based compound for the topical treatment of psoriasis and development of a therapeutic platform for the treatment of numerous immune-deficient diseases. Psoriasis remains a chronic skin disease limited to ineffective topical treatments or dangerous, and sometimes deadly class-I steroids and oral immune-suppressants.